AstraZeneca rejects reports of low COVID-19 vaccine efficacy rate

• AstraZeneca (NASDAQ:AZN) has called the reports of low efficacy rate attributed to its COVID-19 vaccine as "completely incorrect" Reuters reports.
• The vaccine co-developed by AstraZeneca and the University Oxford had an efficacy of 8% or less than 10% in those above 65, German daily papers Handelsblatt and Bild said on Monday in separate reports, respectively.
• The German government did not expect the vaccine to receive EU approval for the age group, the reports have added further.
• The COVID-19 vaccine with emergency approval in many countries, including the U.K. and India, is likely to undergo the EMA (European Medicines Agency) review this week for conditional approval.